HIV/AIDS studies
A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Adults with HIV-1 Infection
The primary aim of this study is to evaluate the efficacy and safety of STP0404 in HIV infected patients.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
PPD Development, LPFunding Years:
2023 - 2027Research Categories:
HIV/AIDSA Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in combination with CAB LA to Standard of Care in Virologi
The primary aim of this study is to evaluate the efficacy and safety of VH3810199 with rHuPH20 in HIV infected patients.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
GlaxoSmithKline, LLCFunding Years:
2023 - 2028Research Categories:
HIV/AIDSA Phase 2b Single Arm, Repeat Dose Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of a New Formulation of Cabotegravir LA Injected Intramuscularly Q4M in Adolescent and Adult Participants at Risk of HIV Acquisition
The primary aim of this study is to evaluate the efficacy and safety of cabotegravir LA in prevention of HIV infection.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
GlaxoSmithKline, LLCFunding Years:
2024 - 2029Research Categories:
HIV/AIDSA PHASE 3 OPEN-LABEL CLINICAL STUDY OF DORAVIRINE/ISLATRAVIR (DOR/ISL [100 MG/0.25 MG]) ONCE DAILY FOR THE TREATMENT OF HIV-1 INFECTION IN PARTICIPANTS WHO PREVIOUSLY RECEIVED DOR/ISL (100 MG/0.75 MG) QD IN A PHASE 3 CLINICAL STUDY
The primary aim of this study is to evaluate the efficacy and safety of doravirine/islatravir when patients who are virologically suppressed on their prior agent are switched.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
Merck Sharp and Dohme Corp.Funding Years:
2023 - 2029Research Categories:
HIV/AIDSA Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy
The primary aim of this study is to evaluate the efficacy and safety of doravirine/islatravir when patients who are virologically suppressed on their prior agent are switched.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
Merck Sharp and Dohme Corp.Funding Years:
2023 - 2029Research Categories:
HIV/AIDSA Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
The primary aim of this study is to evaluate the efficacy and safety of islatravir/lenacapavir in HIV infection.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
Gilead Sciences, Inc.Funding Years:
2024 - 2029Research Categories:
HIV/AIDSA Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
The primary aim of this study is to evaluate the efficacy and safety of islatravir/lenacapavir in HIV infection.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
Gilead Sciences, Inc.Funding Years:
2024 - 2029Research Categories:
HIV/AIDSAddressing cancer treatment disparities for persons with HIV
This study is to investigate disparities by HIV status and modifiable risk factors for delays in cancer treatment initiation, treatment completion, and short- and long-term adverse events for persons with HIV (PWH) who were members of the Veteran’s Administration or Kaiser Permanente, the two largest healthcare systems in the United States. Study findings will provide necessary data to inform HIV-specific cancer treatment guidelines and improve cancer care delivery and outcomes for PWH.
CDC/Kaiser PrEP Data
The primary aim of this study is to evaluate patterns of PrEP utilization.
Principal Investigator:
William J. Towner, MD, FACP, FIDSAFunding Source:
Centers for Disease Control and Prevention (CDC)Funding Years:
2024 - 2026Research Categories:
HIV/AIDSDeveloping an HIV Specific-Specific Prevention Index Using Electronic Medical Record (HIV PI)
The goals of this study are to assess in HIV-infected patients, the degree of association between successful general clinical care by HIV disease-treating providers (reflected in overall adherence to recommended general prevention and screening guidelines) and higher-quality HIV-specific care and related clinical outcome.
Principal Investigator:
Chun Chao, PhD, MSFunding Source:
Agency for Healthcare Research and Quality (AHRQ)Funding Years:
2010 - 2013Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Cardiovascular-Kidney-Metabolic Health and Risk for Cardiovascular Disease
The U.S. Ending the HIV Epidemic initiative aims to expand HIV pre-exposure prophylaxis (PrEP) provision to over a half million at-risk Americans by 2025. This multisite cohort study would be the first to systematically assess the impact of PrEP on cardiovascular-kidney-metabolic health among diverse populations using comprehensive electronic health record data from three large integrated healthcare systems. The knowledge gained from this study will help inform evidence-based PrEP guidelines and develop tailored prevention strategies to reduce cardiovascular morbidity and mortality among people taking PrEP.